EGFR and non-small cell lung carcinoma: To investigate the potential antitumor effect of anlotinib and in combination with osimertinib in osimertinib‐resistant EGFR‐T790M mutant NSCLC, we performed cell growth and viability assay in H1975 and osimertinib‐resistant H1975 cell line (H1975OR) treated with anlotinib and/or osimertinib.